Organizational, direct support, and general support maintenance repair parts and special tools list (including depot maintenance repair parts and speial tools) : air conditioner, 36,000/60,000 Btu/hr, gasoline engine driven, skid mounted, trailer mountable (Carrier-Transicold Company model 76ED51-124) FSN 4120-935-5347).

Includes index.

Organizational maintenance repair parts and special tools lists : air conditioner, vertical compact, floor mounted, 36,000 BTU/hr cooling, 30,000 BTU/hr heating; 208 volt, 3 phase, 50/60 hertz, (Trane model MAC6V40-340-2) FSN 4120-935-5421, 208 volt, 3 phase, 400 hertz (Trane model MAC4V40-340-3) FSN 4120-935-5418.

Includes index.

Direct and general support and depot maintenance repair parts and special tools lists : air conditioner; vertical compact, floor mounted, 36,000 BTU/hr cooling, 30,000 BTU/hr heating; 208 volt, 3 phase, 50/60 hertz, (Trane model MAC 6V40-340-2) FSN 4120-935-5421, 208 volt, 3 phase, 400 hertz (Trane model MAC 4V40-340-3) FSN 4120-935-5418.

Includes index.

Organizational, direct support and general support maintenance repair parts and special tools list for air conditioner, horizontal, compact, 36,000 BTU/hr, cooling, 31,000 BTU/hr, heating, 208 volt, 3 phase 50/60 hertz, model CH40-5/6-08, NSN 4120-01-122-0628.

Includes index.

Operator's, organizational, direct support, and general support maintenance manual : air conditioner, vertical, compact, 36,000 BTU/hr cooling, 28,600 BTU/hr heating, 208 volt, 3 phase, 400 hertz, NSN 4120-01-110-2034.

Shipping list no.: 89-467-P.

Organizational, direct support and general support maintenance repair parts and special tools list (including depot maintenance repair parts and special tools) for air conditioner, compact, vertical, 36,000 BTU/hr cooling, 28,600 BTU/hr heating, 208 volt, 3 phase, 400 hertz, Keco model F36T4-2, NSN 4120-01-072-6388.

Includes index.

Operator's, organizational, direct support and general support maintenance manual : air conditioner, vertical compact, 36,000 BTU/hr cooling, 28,600 BTU/hr heating, 208 volt, 3 phase, 400 hertz, Keco model F36T4-2, NSN-4120-01-072-6388.

Includes index.

Operator's, unit, intermediate direct support and intermediate general support maintenance : heater, duct type, portable, HDU-36/E, 120,000 BTU, model H82.

Includes index.

Workers in subjects pertaining to agriculture in state agricultural colleges and experiment stations, 1935-36 /

Includes index.

Sales of cotton for future delivery, 1925-26 to 1935-36 /

"September 1937."

Engine, diesel, marine : Enterprise models DMQ-36 and DMQ-38.

Includes index.

National Park Seminary, a junior college, incorporated, for young women, Washington, D. C. suburbs [Calendar̈

Mode of access: Internet.

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C

BACKGROUND: Sustained virological response (SVR) is the primary objective in the treatment of chronic hepatitis C (CHC). Results from a recent clinical trial of patients with previously untreated CHC demonstrate that the combination of peginterferon alpha-2a and ribavirin produces a greater SVR than interferon alpha-2b and ribavirin combination therapy. However, the cost-effectiveness of peginterferon alpha-2a plus ribavirin in the U.S. setting has not been investigated. METHODS: A Markov model was developed to investigate cost-effectiveness in patients with CHC using genotype to guide treatment duration. SVR and disease progression parameters were derived from the clinical trials and epidemiologic studies. The impact of treatment on life expectancy and costs were projected for a lifetime. Patients who had an SVR were assumed to remain virus-free for the rest of their lives. In genotype 1 patients, the SVRs were 46% for peginterferon alpha-2a plus ribavirin and 36% for interferon alpha-2b plus ribavirin. In genotype 2/3 patients, the SVRs were 76% for peginterferon alpha-2a plus ribavirin and 61% for interferon alpha-2b plus ribavirin. Quality of life and costs were based on estimates from the literature. All costs were based on published U.S. medical care costs and were adjusted to 2003 U.S. dollars. Costs and benefits beyond the first year were discounted at 3%. RESULTS: In genotype 1, peginterferon alpha-2a plus ribavirin increases quality-adjusted life expectancy (QALY) by 0.70 yr compared to interferon alpha-2b plus ribavirin, producing a cost-effectiveness ratio of $2,600 per QALY gained. In genotype 2/3 patients, peginterferon alpha-2a plus ribavirin increases QALY by 1.05 yr in comparison to interferon alpha-2b plus ribavirin. Peginterferon alpha-2a combination therapy in patients with HCV genotype 2 or 3 is dominant (more effective and cost saving) compared to interferon alpha-2b plus ribavirin. Results weighted by genotype prevalence (75% genotype 1; 25% genotype 2 or 3) also show that peginterferon alpha-2a plus ribavirin is dominant. Peginterferon alpha-2a and ribavirin remained cost-effective (below $16,500 per QALY gained) under sensitivity analyses on key clinical and cost parameters. CONCLUSION: Peginterferon alpha-2a in combination with ribavirin with duration of therapy based on genotype, is cost-effective compared with conventional interferon alpha-2b in combination with ribavirin when given to treatment-naive adults with CHC.

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C

Background/Aims: Peginterferon alfa-2a plus ribavirin improves sustained virological responses compared with interferon alfa-2b and ribavirin, or peginterferon alfa-2a alone in chronic hepatitis C. We examined the impact of these treatments on health related quality of life (HRQOL). Methods: Patients (n = 1121) were randomized to peginterferon alfa-2a weekly plus ribavirin or placebo, or interferon alfa-2b thrice weekly plus ribavirin. HRQOL was assessed with the SF-36 Health Survey and Fatigue Severity Scale (FSS). Results: Patients receiving peginterferon alfa-2a plus ribavirin reported better HRQOL than those receiving interferon alfa-2b plus ribavirin. These differences were statistically significant for three SF-36 domains and both FSS scores (p < = 0.05). Patients receiving peginterferon alfa-2a plus placebo had the least impairment; adding ribavirin significantly decreased five domains of the SF-36 and both FSS scores. Sustained virological response was associated with improvement at follow-up on all SF-36 and FSS scores. Conclusions: The effects of combination therapy on HRQOL and fatigue are less with peginterferon alfa-2a plus ribavirin than interferon alfa-2b plus ribavirin. Each medication in combination therapy with interferon and ribavirin, affects patients' quality of life differently. Understanding the relationship of specific therapeutic options to HRQOL may help physicians minimize the impact of therapy on HRQOL. (C) 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.